spacer
home > ebr > summer 2017 > sustainable solutions
PUBLICATIONS
European Biopharmaceutical Review

Sustainable Solutions

EBR: Sobi has been involved in this field for more than three decades. Can you describe some of the greatest changes the company has seen during that time, both in the industry generally and your specific area of expertise?

Hege Hellström and Neil Dugdale: Our company has grown over the past 30 years from a Nordic-focused organisation to one with a presence in the rest of Europe, North Africa and the Middle East, but we have always remained patient-focused. One of the greatest changes Sobi has seen in the rare disease space during this time was the introduction of the European orphan drug legislation in 1999, encouraging pharmaceutical companies to focus on rare diseases, which, in turn, has led to more treatments for patients.

Rare diseases are often neglected because the drugs manufactured are intended for a small number of patients suffering from rare conditions and, as such, do not generate much financial benefit. Would you say that more incentives are needed to encourage pharma firms to develop treatments for these kinds of patients?

Sobi feels it is important that rare disease companies bring treatments to market as early as possible to give patients the best chance. We therefore welcome early collaborative dialogue with all stakeholders, including payers and governing bodies, to ensure that innovative products are brought to market in a sustainable way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hege Hellström has been working at Sobi since 2013 as the President for the Europe, Middle East and North Africa region. She has over 25 years’ experience in various national and international sales, marketing and leadership positions in several therapeutic areas including diagnostics, nephrology, endocrinology, gastrointestinal, rare diseases and haemophilia.

Neil Dugdale is General Manager for the UK and Ireland at Sobi since 2015, but started his career at Merck in 1994 as a Sales Representative and, after working in a number of commercial roles, became Business Unit Director in 2003. Following Merck’s acquisition of Serono, Neil set up his own consultancy in 2007, working with a number of pharma clients including Eisai and Merck Serono. He re-joined the latter in 2013 as an Interim Consultant and then became permanent Oncology Director.

spacer
Hege Hellström
spacer
spacer
spacer
Neil Dugdale
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala launches a completely new probe for the measurement of hydrogen peroxide


More info >>

White Papers

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

TBM Consulting Group

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?” Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
More info >>

 
Industry Events

7th American Drug Delivery & Formulation Summit

28-29 August 2017, The Westin Copley Place Boston Hotel

Innovative solutions to the greatest challenges in pharmaceutical development
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement